Pyxis Oncology Appoints ADC Expert Nelson Azoulay to Advance Lead Clinical Asset
PYXS•Pyxis Oncology has appointed Nelson Azoulay as Chief Business Officer; he has over 15 years of biopharma strategy and ADC expertise and will lead corporate development to advance micvotabart pelidotin. Azoulay previously oversaw business development at Flagship Pioneering and drove ImmunoGen's acquisition by AbbVie.
1. Appointment Details
Pyxis Oncology has appointed Nelson Azoulay as Chief Business Officer, effective immediately. He will oversee corporate development strategy, partnerships and value-creating transactions as the company advances its lead clinical asset, micvotabart pelidotin (MICVO).
2. Experience and Background
Azoulay brings more than 15 years of biopharma experience in strategy and business development, including roles at Flagship Pioneering and ImmunoGen. He led ImmunoGen's mid- to long-term strategy, supported fundraising and facilitated its acquisition by AbbVie in 2024.
3. Strategic Focus
In his new role, Azoulay will target strategic collaborations to accelerate MICVO's Phase 1 trials in recurrent and metastatic head and neck squamous cell carcinoma. His deep antibody-drug conjugate expertise is expected to drive partnerships, external relationships and long-term value creation.
